74733-28-1

Basic information

• Product Name: Methyl 4-(bromomethyl)-2-methylbenzoate
• Synonyms: Methyl 4-(bromomethyl)-2-methylbenzoate
• CAS NO: 74733-28-1
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.09714
• Mol File: 74733-28-1.mol

Chemical Properties

• Boiling Point: 295.6±28.0 °C(Predicted)
• Appearance: /
• Density: 1.404±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 4-(bromomethyl)-2-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(bromomethyl)-2-methylbenzoate(74733-28-1)
• EPA Substance Registry System: Methyl 4-(bromomethyl)-2-methylbenzoate(74733-28-1)

Safety Data

• Hazardous Substances Data: 74733-28-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 4-(bromomethyl)-2-methylbenzoate is used as a building block in organic synthesis for the creation of a variety of compounds. Its reactive bromomethyl group allows for versatile chemical reactions, facilitating the formation of new molecules with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Methyl 4-(bromomethyl)-2-methylbenzoate serves as an important intermediate. Its unique structure and reactivity make it suitable for the development of new drugs and active pharmaceutical ingredients. Methyl 4-(bromomethyl)-2-methylbenzoate's ability to participate in cross-coupling reactions is particularly valuable in the synthesis of complex organic molecules with therapeutic potential.
Used in Chemical Product Production:
Methyl 4-(bromomethyl)-2-methylbenzoate is also utilized in the production of various chemical products. Its versatility in cross-coupling reactions contributes to the synthesis of a wide range of chemical entities, including specialty chemicals, agrochemicals, and materials with specific properties for industrial applications.

Upstream product

• 23617-71-2 2,4-dimethyl-benzoic acid methyl ester 
• 67-56-1 methanol 
• 611-01-8 2,4-dimethyl-benzoic acid 
• 530145-28-9 methyl 4-(hydroxymethyl)-2-methylbenzoate 
• 21900-42-5 2,4-dimethylbenzoyl chloride 

Downstream Products

• 861555-67-1 4-(hydroxymethyl)-2-methylbenzoic acid 
• 1398397-78-8 methyl 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoate 
• 1398397-72-2 methyl 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoate 
• 133052-40-1 4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-2-methylbenzoic acid 
• 77837-62-8 (1E,3E)-1-(4-carboethoxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 77837-64-0 (1Z,3E)-1-(4-carboethoxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 77837-63-9 (1E,3E)-1-(4-carboxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 77837-69-5 (E)-3-(4-carboethoxy-3-methylphenyl)-2-methylpropenal 
• 77837-80-0 4-((E)-3-Hydroxy-2-methyl-propenyl)-2-methyl-benzoic acid ethyl ester 
• 77837-67-3 1-(4-carboethoxy-3-methylphenyl)-2-methyl-1-propene 
• 71441-11-7 4-carboethoxy-3-methylbenzaldehyde 
• 133052-57-0 methyl-4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-2-methylbenzoate 
• 1268243-58-8 methyl 2-methyl-4-(methylsulfonylmethyl)benzoate 

Relevant articles and documents

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Mild Benzylic Monobromination of Methyl Toluates in Aqueous CTAB

A strategy has been developed for the regioselective monobromination of methyl toluates by using tert-butylhydrogen peroxide and potassium bromide (TBHP/KBr) in a cetyltrimethylammonium bromide (CTAB) micellar medium. Ultrasonic and microwave-assisted protocols recorded increased rates and product yields under mild reaction conditions, coupled with a straightforward isolation procedure.

PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING

The invention provides novel inhibitors of hedgehog signaling that are useful as s therapeutic agent for treating malignancies where the compounds have the general formula (I): where A, X, Y R1, R2, R3, R4, m and n are as described herein.

Pyridyl inhibitors of hedgehog signalling

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.

FUSED PYRIMIDINONE MATRIX METALLOPROTEINASE INHIBITORS

Selective MMP-13 inhibitors are fused pyrimidinones of the formula or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical X is O, S, SO, SO2, NR5, or CH 2; B is O or NR5; or A and B are taken together to form--C≡C--; R1, R4, and R 5 are hydrogen, alkyl, alkenyl, alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, C1-C6 alkanoyl, or (CH2)n heteroaryl; R2 and R3 are hydrogen, alkyl, alkenyl, alkynyl CN, NO2, NR 4R5, (CH2)n cycloalkyl, (CH2) n aryl, or (CH2)n heteroaryl; R2 may further be halo; n is an integer of from 0 to 5; and R4 and R5 when taken together with a nitrogen to which they are both attached complete a 3-to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that R1 and R3 are not both selected from hydrogen and C1-C6 alkyl.

Benz[4,5]imidazole-containing angiotensin antagonists

The invention concerns novel heterocyclic compounds of the formula I as defined herein and their physiologically acceptable salts, together with pharmaceutical compositions containing them. The heterocyclic compounds antagonize the actions of angiotensin II and are of value in treating diseases or medical conditions such as hypertension and congestive heart failure in warm-blooded animals. The invention further includes processes for the manufacture of the novel compounds and their use in medical treatment.

Secondary amines, their preparation and use in pharmaceutical compositions

The compounds of the formula (II): STR1 and their pharmaceutically acceptable salts wherein R1 is a hydrogen, fluorine or chlorine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R2 is a hydrogen, fluorine or chlorine atom or a hydroxyl group; R3 is a hydrogen or chlorine atom or a hydroxyl group; R4 is a carboxylic acid group or a salt, ester or amide thereof; R5 is a hydrogen, chlorine or fluorine atom or a methyl, methoxyl or hydroxyl group or a carboxylic acid group or a salt, ester or amide thereof; R6 is a hydrogen atom or a methyl, or propyl group; X is an oxygen atom or a bond; and Y is an alkylene group of up to 6 carbon atoms or a bond have been found to possess anti-obesity and/or antihyperglycaemic activity.